Off

It’s been six years since the launch of startup company , co-founded by Professor Mark Rentschler of the Paul M. Rady Department of Mechanical Engineering. The company has seen great success, including the development of a medical device designed to enable more efficient procedures in the small bowel region.

Today, with the help of a $4.5 million award through the Anschutz Acceleration Initiative (AAI), Rentschler and his colleagues are working to bring two new products to the market that will transform these types of procedures even further.

“We brought our first product out on the market in 2024,” said Rentschler, also a faculty member in biomedical engineering (BME) and robotics. “We are planning to bring a second and third product to the market in 12-18 months, and we are extremely excited to get these devices in the hands of interventional endoscopists.”

Professor Mark Rentschler holding Aspero Medical's patented Ancora-SB balloon overtube.

In 2023, Aspero received clearance from the Food and Drug Administration (FDA) to market and sell the Ancora-SB device. The product is used during endoscopy procedures to diagnose and treat small bowel diseases.

According to Rentschler, operating within the small intestine can be time consuming and technically challenging. Equipped with a patented micro-textured balloon, the Ancora-SB overtube is designed to provide more traction and anchoring consistency than smooth latex or smooth silicone balloon overtube competitors.

“Balloon overtubes for small bowel procedures have been around for about a decade,” said Rentschler. “We’re not looking to change the small bowel enteroscopy procedure, but instead improve balloon anchoring performance during these procedures in the small bowel.”

Ancora-SB has allowed Aspero to prove their worth in hospitals. Their next products expand on this concept, of course, with additional features that can facilitate a less invasive interventional procedure than traditional open surgery.

The next generation balloon overtube will be used to remove cancerous lesions in the large bowel region. It features an extra working channel that allows for an additional tool to be utilized alongside the visualization scope. This offers physicians more control, access, and stabilization when maneuvering through the colon and performing advanced interventional procedures.

“Conceptually, these devices will enable triangulated surgery with two tools and centralized visualization so that physicians can more efficiently perform surgery from inside the lumen,” Rentschler said. “Instead of historically invasive procedures, where the patient is cut open, and the cancerous bowel region is removed, we’re assisting physicians as they remove the cancer from the inside of the lumen during an outpatient procedure.

“It's much less invasive, with potentially tremendous cost savings, and numerous benefits for the patient.”

Aspero’s third product will be another balloon overtube, this time with a working channel that enables minimally invasive cancer removal in the esophagus and stomach regions of the gastrointestinal tract. 

Rentschler showcasing all three of the medical devices in Aspero Medical's multi-product platform, including their two new highly anticipated devices.

Rentschler and his team say the two upcoming devices have the potential to replace a large, and growing, number of today’s conventional surgical procedures in the gastrointestinal region by enhancing safety and efficiency while reducing patient recovery time. Moving procedures from inpatient surgery to outpatient endoscopy can generate potential cost savings of up to 50 percent or more.

“Everyone knows this is the direction we need to go. Clinical outcomes from these types of procedures are incredibly strong, but the techniques and devices aren’t widely available yet,” said Rentschler. “We are creating products that help physicians and patients feel safe and comfortable without overcomplicating things. The paradigm is rapidly shifting, and we endeavor to push endoscopy forward.”

The company is currently finalizing the design of the second product. It’s about six months further along in development than the third product, but Rentschler says they are looking to have both devices FDA cleared by the end of 2026. 

When all three devices hit the market, Aspero will look to market a portfolio of products, rather than a single tool. But further innovation is on the horizon, this time incorporating the Ancora balloon technology with a robotic element.

“Ancora is a multi-product platform focusing on the small bowel, large bowel, stomach and esophageal regions,” Rentschler said. “Our next potential venture will be in flexible robots. We’ll continue with our balloon overtubes, but as anchoring platforms to be used with flexible robotic endoscopy systems.”

Until then, Rentschler and company are full steam ahead on these next products. The $4.5 million AAI grant is being offered over a four year span, but they anticipate spending that money much sooner so they can get the devices out on the market and begin positively impacting patients and physicians everywhere.

But that’s not their only goal. With a lot of Colorado involved in the company’s revolutionizing technology, Rentschler hopes to also tell another story.

“I started Aspero Medical with Dr. Steven Edmundowicz at ���������� Anschutz. We’ve received a number of grants from the state of Colorado and everyone involved is invested in our vision,” said Rentschler. “We believe that a rising tide raises all boats, and when we think of Aspero, we want it to be a successful Colorado story.”

Off

Off

Watch Jacob Segil, CEO of Afference and research professor in the Paul M. Rady Department of Mechanical Engineering, showcase a new piece of haptic technology in an episode of Freethink's Hard Reset docuseries that will "redraw the borders of reality."

Off

Off

Off

Off

Off

Off

Off